<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012973</url>
  </required_header>
  <id_info>
    <org_study_id>14130</org_study_id>
    <secondary_id>2009-010973-19</secondary_id>
    <nct_id>NCT01012973</nct_id>
  </id_info>
  <brief_title>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</brief_title>
  <acronym>GALILEO</acronym>
  <official_title>A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into
      the eye on vision function in subjects with macular edema as a consequence of central retinal
      vein occlusion
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. However, because this was assessed at the screening visit, subjects may have had a higher BCVA recorded at the baseline visit and would not have been excluded from the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Developed Neovascularization During the First 24 Weeks</measure>
    <time_frame>From baseline until Week 24</time_frame>
    <description>Formation of blood vessels in the anterior segment, optic disc, or elsewhere in the fundus up to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.</description>
    <arm_group_label>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham treatment</intervention_name>
    <description>Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.</description>
    <arm_group_label>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</arm_group_label>
    <arm_group_label>Sham treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Center-involved macular edema secondary to central retinal vein occlusion (CRVO) for
             no longer than 9 months with mean central subfield thickness ≥ 250 μm on optical
             coherence tomography (OCT)

          -  Adults ≥ 18 years

          -  Early treatment diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA)
             of 20/40 to 20/320 (73 to 24 letters) in the study eye

        Exclusion Criteria:

          -  Any prior treatment with anti-VEGF agents in the study eye (Pegaptanib sodium,
             anecortave acetate, bevacizumab, ranibizumab, etc.) or previous administration of
             systemic anti-angiogenic medications

          -  Prior panretinal laser photocoagulation or macular laser photocoagulation in the study
             eye

          -  CRVO disease duration &gt; 9 months from date of diagnosis

          -  Previous use of intraocular corticosteroids in the study eye or use of periocular
             corticosteroids in the study eye within the 3 months prior to Day 1

          -  Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or
             preretinal fibrosis involving the macula in either the study eye or fellow eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chatswood</city>
        <state>New South Wales</state>
        <zip>2067</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <state>Cedex 12</state>
        <zip>75557</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <state>Cedex 1</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ludwigshafen</city>
        <state>Rheinland-Pfalz</state>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>06067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <zip>H-8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <zip>10122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urayasu</city>
        <state>Chiba</state>
        <zip>279-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggido</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110 744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <zip>1050</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <results_reference>
    <citation>Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013 Mar;97(3):278-84. doi: 10.1136/bjophthalmol-2012-301504. Epub 2013 Jan 7. Erratum in: Br J Ophthalmol. 2015 Dec;99(12):1746.</citation>
    <PMID>23298885</PMID>
  </results_reference>
  <results_reference>
    <citation>Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014 Jan;121(1):202-8. doi: 10.1016/j.ophtha.2013.08.012. Epub 2013 Sep 29.</citation>
    <PMID>24084497</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <results_first_submitted>October 23, 2012</results_first_submitted>
  <results_first_submitted_qc>October 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 22, 2012</results_first_posted>
  <disposition_first_submitted>January 26, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 26, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 30, 2012</disposition_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <keyword>Central Retinal Vein Occlusion</keyword>
  <keyword>CRVO</keyword>
  <keyword>VEGF Trap-Eye</keyword>
  <keyword>best-corrected visual acuity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aflibercept Injection First, Then Aflibercept Injection</title>
          <description>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.</description>
        </group>
        <group group_id="P2">
          <title>Sham Treatment First, Then Aflibercept Injection</title>
          <description>Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="104">Safety Population: Participants received treatment</participants>
                <participants group_id="P2" count="68">Safety Population: Participants received treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Fulfilled Requirements of FAS Population</title>
              <participants_list>
                <participants group_id="P1" count="103">Full Analysis Set (FAS) Population: Participants received treatment with post baseline measurements</participants>
                <participants group_id="P2" count="68">Full Analysis Set (FAS) Population: Participants received treatment with post baseline measurements</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 24, From FAS</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 52, From FAS</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>(Overseas travel - indefinite period)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Increase in vis. acuity, never injected</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</title>
          <description>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.</description>
        </group>
        <group group_id="B2">
          <title>Sham Treatment</title>
          <description>Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="12.3"/>
                    <measurement group_id="B2" value="63.8" spread="13.3"/>
                    <measurement group_id="B3" value="61.5" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Best Corrected Visual Acuity (BCVA) letter scores</title>
          <description>Infiormation retrieved from all baseline participants. Only participants with a ETDRS (Early Treatment Diabetic Retinopathy Study) Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters were included; a higher score represents better functioning.</description>
          <units>Letters correctly read</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="15.7"/>
                    <measurement group_id="B2" value="50.9" spread="15.4"/>
                    <measurement group_id="B3" value="52.5" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with baseline retinal perfusion</title>
          <description>Retinal perfusion defined as less than 10 disc areas of capillary nonperfusion using fluorescein angiography (FA)</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Perfused</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonperfused</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indeterminate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Retinal Thickness by Optical Coherence Tomography (OCT)</title>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="682.78" spread="233.36"/>
                    <measurement group_id="B2" value="638.66" spread="224.69"/>
                    <measurement group_id="B3" value="665.34" spread="230.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline intraocular pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" spread="2.8"/>
                    <measurement group_id="B2" value="14.4" spread="2.7"/>
                    <measurement group_id="B3" value="14.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with time since Central retinal vein occlusion (CRVO) diagnosis</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;= 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total score</title>
          <description>The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.66" spread="13.06"/>
                    <measurement group_id="B2" value="78.94" spread="14.00"/>
                    <measurement group_id="B3" value="79.38" spread="13.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>European questionnaire 5 dimensions (EQ-5D) total score</title>
          <description>The EQ-5D total score ranges from -0.594 to 1.000 with -0.594 being the worst.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.87" spread="0.15"/>
                    <measurement group_id="B2" value="0.86" spread="0.16"/>
                    <measurement group_id="B3" value="0.87" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures</title>
        <description>Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</title>
            <description>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures</title>
          <description>Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.</description>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2"/>
                    <measurement group_id="O2" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of difference of Eylea minus Sham of 0 was tested. In the database close after Week 24, basis for primary efficacy evaluation, 56 Sham / 96 Eylea subjects were considered as week 24 completers.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH adjusted difference</param_type>
            <param_value>38.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.4</ci_lower_limit>
            <ci_upper_limit>52.1</ci_upper_limit>
            <estimate_desc>The estimate is calculated as Eylea minus Sham. A positive value shows Eylea showed a higher BCVA total score compared to Sham.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)</title>
        <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. However, because this was assessed at the screening visit, subjects may have had a higher BCVA recorded at the baseline visit and would not have been excluded from the study.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</title>
            <description>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)</title>
          <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. However, because this was assessed at the screening visit, subjects may have had a higher BCVA recorded at the baseline visit and would not have been excluded from the study.</description>
          <population>Full analysis set</population>
          <units>Letters correctly read</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="17.1"/>
                    <measurement group_id="O2" value="54.3" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was equality in change from baseline to Week 24 in BCVA total letter score between Eylea and Sham. If primary efficacy was successful, secondary efficacy endpoints were tested in a pre-specified fixed sequence testing procedure. Change in BCVA letter score was to be tested first in this sequence.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>As primary efficacy evaluation was significant, and this p-value was below significance level of two-sided &lt;.05, the fixed sequence testing did continue with next secondary endpoint.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA, adjusting for region and baseline BCVA category as fixed factors.</method_desc>
            <param_type>Difference in Least square means</param_type>
            <param_value>14.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.8</ci_lower_limit>
            <ci_upper_limit>18.7</ci_upper_limit>
            <estimate_desc>The difference is calculated as Eylea minus Sham. A positive value indicates Eylea showed a higher change in BCVA total score until week 24 compared to Sham.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF</title>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full-Analysis Set with assessment for this outcome measure; imputation technique: LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</title>
            <description>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF</title>
          <population>Full-Analysis Set with assessment for this outcome measure; imputation technique: LOCF</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-448.58" spread="256.02"/>
                    <measurement group_id="O2" value="-169.27" spread="224.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was equality in change from baseline to Week 24 in central retinal thickness between Eylea and Sham. If primary efficacy was successful, secondary efficacy end points were to be tested in a pre-specified fixed sequence testing procedure. Change in central retinal thickness was to be tested at second place in this sequence.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>As fixed sequence testing did reject nullhypothesis of change from baseline in BCVA until week 24, and this p-value was below significance level of two-sided &lt;.05, the fixed sequence testing did continue with next secondary endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA, stratified by region and baseline BCVA category, baseline central retinal thickness added as covariate.</method_desc>
            <param_type>Difference in Least square (LS) means</param_type>
            <param_value>-239.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-286.31</ci_lower_limit>
            <ci_upper_limit>-192.53</ci_upper_limit>
            <estimate_desc>The difference is calculated as Eylea minus Sham. A negative value indicates Eylea showed a higher reduction in change in central retinal thickness until week 24 compared to Sham.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Developed Neovascularization During the First 24 Weeks</title>
        <description>Formation of blood vessels in the anterior segment, optic disc, or elsewhere in the fundus up to Week 24</description>
        <time_frame>From baseline until Week 24</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</title>
            <description>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Developed Neovascularization During the First 24 Weeks</title>
          <description>Formation of blood vessels in the anterior segment, optic disc, or elsewhere in the fundus up to Week 24</description>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any neovascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior segment neovascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neovascularization of the optic disc (NVD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neovascularization elsewhere in the fundus (NVE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nullhypothesis of no difference in development of neovascularizations between Eylea and Sham group was tested. (Any neovascularization)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5947</p_value>
            <p_value_desc>As fixed sequence testing did reject nullhypothesis of change from baseline in CRT until week 24, and this p-value was not below significance level of two-sided &lt;.05, the fixed sequence testing did end with this evaluation.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochrane-Mantel-Haenszel test, stratified by region and baseline BCVA category.</method_desc>
            <param_type>CMH adjusted Difference</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF</title>
        <description>The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full-Analysis Set with assessment for this outcome measure; imputation technique: LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</title>
            <description>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF</title>
          <description>The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight</description>
          <population>Full-Analysis Set with assessment for this outcome measure; imputation technique: LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.46" spread="9.55"/>
                    <measurement group_id="O2" value="3.55" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS means</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
            <estimate_desc>As the fixed sequence of secondary endpoints stopped with proportion of neovascularizations developed until week 24, 95% confidence interval is only of descriptive nature.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF</title>
        <description>EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full-Analysis Set with assessment for this outcome measure; imputation technique: LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</title>
            <description>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF</title>
          <description>EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).</description>
          <population>Full-Analysis Set with assessment for this outcome measure; imputation technique: LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" spread="0.139"/>
                    <measurement group_id="O2" value="-0.002" spread="0.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>As the fixed sequence of secondary endpoints stopped with proportion of neovascularizations developed until week 24, 95% confidence interval is only of descriptive nature.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aflibercept Injection (Until Week 20)</title>
          <description>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20. Participants were observed until Week 24. Participants in the safety population were at risk.</description>
        </group>
        <group group_id="E2">
          <title>Sham Treatment (Until Week 20)</title>
          <description>Participants received sham treatment administered every 4 weeks from Day 1 through Week 20. Participants were observed until Week 24. Participants in the safety population were at risk.</description>
        </group>
        <group group_id="E3">
          <title>Aflibercept Injection (Until Week 48)</title>
          <description>Participants who continued the study drug until Week 24 received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Participants were observed from Week 24 until Week 52. Participants in the safety population that completed Week 24 were at risk.</description>
        </group>
        <group group_id="E4">
          <title>Sham Treatment (Until Week 48)</title>
          <description>Participants who continued the study drug until Week 24 received sham treatment administered every 4 weeks from Week 24 to Week 48. Participants were observed from Week 24 until Week 52. Participants in the safety population that completed Week 24 were at risk.</description>
        </group>
        <group group_id="E5">
          <title>Aflibercept Injection Continued (Until Week 68)</title>
          <description>Participants on IAI who continued the study drug until Week 52, received 2 mg dose of IAI depending on the study retreatment criteria at Week 52, 60 and 68. Participants were observed starting from Week 52. Participants in the safety population that completed Week 52 were at risk.</description>
        </group>
        <group group_id="E6">
          <title>Sham Treatment Then Aflibercept Injection (Until Week 68)</title>
          <description>Participants on sham treatment switched to IAI, received a 2 mg dose of IAI at Week 52 and depending on the study retreatment criteria at Week 60 and 68. Participants were observed starting from Week 52. Participants in the safety population that completed Week 52 were at risk.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Iris neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Macular ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Laryngeal granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Ischaemic heart disease prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Macular ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Optic disc vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Retinal exudates</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Retinal vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Visual acuity tests abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publishing of result communication only after Bayer´s written approval. Manuscript to Bayer sixty days before public release. If no written Bayer comment within 60 days consider approval given. If multi-site study, principal investigator (PI) not do independently publish results before publication of the multi-site paper, but PI not restricted from 24 months from study to completion onwards.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

